Over the past decade many large randomized trials have been conducted in patients with
locally advanced or metastatic non-small cell lung cancer (NSCLC); however, no single …

Introduction: For patients with advanced NSCLC, treatment outcomes are still disappointing
and the search for new active and safe drugs is warranted. The chemotherapeutic agent …

The use of chemotherapy in the treatment of early and advanced non-small-cell lung cancer
(NSCLC) has increased during the past decade. One of the main reasons for the increased …

Until recently, the treatment of non–small cell lung cancer (NSCLC) was limited to the
cisplatin combinations, including a small number of cytotoxic drugs. More recently …

Pemetrexed is a novel multitargeting antimetabolite that has first-line and second-line
activity against nonsmall cell lung cancer (NSCLC). Phase II studies have shown significant …

Importance of the field: Current therapeutic options for advanced non-small-cell lung cancer
(NSCLC) yield relatively modest improvements in survival leading to an ongoing search for …

INTRODUCTION: The primary objectives of this study were to determine the recommended
dose of pemetrexed and carboplatin in patients with chemo-naive advanced non-small cell …

Purpose: To determine efficacy and toxicity of two pemetrexed-based regimens in
chemonaive patients with locally advanced or metastatic non–small cell lung cancer …

Background Subgroup analyses of randomized studies have consistently shown that
pemetrexed is exclusively effective in non-small-cell lung cancer (NSCLC) other than …

Pemetrexed, a new cytotoxic agent, is a potent inhibitor of thymidylate synthetase and other
folate-dependent enzymes. Firstly, pemetrexed was approved in combination with cisplatin …